These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16782993)

  • 41. Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus.
    Hayden MR; Kolb L; Chowdbury N; Karuparthi PR; Khanna R; Sowers JR
    Mo Med; 2006; 103(5):533-8. PubMed ID: 17133759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients?
    Shah DS; Polkinghorne KR; Pellicano R; Kerr PG
    Nephrology (Carlton); 2008 Dec; 13(8):667-71. PubMed ID: 18761627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction?
    Boos CJ; Lip GY
    Am J Hypertens; 2006 May; 19(5):511-2. PubMed ID: 16647625
    [No Abstract]   [Full Text] [Related]  

  • 44. Letter regarding article by Arnlov et al, "low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals".
    Asselbergs FW; van der Harst P; van Gilst WH
    Circulation; 2006 Mar; 113(10):e406; author reply e406-7. PubMed ID: 16534021
    [No Abstract]   [Full Text] [Related]  

  • 45. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality.
    Klausen KP; Parving HH; Scharling H; Jensen JS
    J Intern Med; 2007 Oct; 262(4):470-8. PubMed ID: 17875184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate.
    Cirillo M; Lanti MP; Menotti A; Laurenzi M; Mancini M; Zanchetti A; De Santo NG
    Arch Intern Med; 2008 Mar; 168(6):617-24. PubMed ID: 18362254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Haemodialysis and hypertension].
    van der Giet M; Zidek W
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2605-9. PubMed ID: 17096308
    [No Abstract]   [Full Text] [Related]  

  • 48. [Microalbuminuria: predictive factor of renal and cardiovascular risk].
    Ruilope LM; Suárez C
    Rev Clin Esp; 1993 May; 192(9):415-6. PubMed ID: 8516504
    [No Abstract]   [Full Text] [Related]  

  • 49. [Microalbuminuria and albuminuria: differential diagnosis and consequences for treatment].
    Koziolek MJ; Bramlage CP; Vasko R; Grupp C; Müller GA
    Dtsch Med Wochenschr; 2009 Aug; 134(34-35):1681-5. PubMed ID: 19707964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anemia and the heart in chronic kidney disease.
    Zalunardo N; Levin A
    Semin Nephrol; 2006 Jul; 26(4):290-5. PubMed ID: 16949467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular risk profile assessment and medication control should come first.
    Zoccali C; Mallamaci F; Tripepi G
    Semin Dial; 2007; 20(5):405-8. PubMed ID: 17897245
    [No Abstract]   [Full Text] [Related]  

  • 52. Microalbuminuria in treated hypertensives: only a mirror image of cardiovascular risk? The HUNT Study, Norway.
    Kvenild K; Romundstad S; Midthjell K; Krüger O; Hallan H; Holmen J
    Scand J Prim Health Care; 2006 Sep; 24(3):145-53. PubMed ID: 16923623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microalbuminuria and cardiovascular disease.
    Weir MR
    Clin J Am Soc Nephrol; 2007 May; 2(3):581-90. PubMed ID: 17699466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular risk with SCORE system in patients with different degree of renal function impairment.
    Deliyska B; Shurliev V; Nenchev N; Krivoshiev S; Strashimirova V
    Med Pregl; 2007; 60 Suppl 2():91-3. PubMed ID: 18928168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.
    Avci E; Coskun S; Cakir E; Kurt Y; Ozgur Akgul E; Bilgi C
    Ren Fail; 2008; 30(8):784-90. PubMed ID: 18791952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Lipids disorders in chronic kidney disease].
    Rozentryt P; Poloński L
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II69-75. PubMed ID: 19813340
    [No Abstract]   [Full Text] [Related]  

  • 57. Cardiovascular risk stratification: an important tool for treatment to lower cardiovascular disease risk.
    Himmelmann A; Kjeldsen S; Hedner T
    Blood Press; 2004; 13(3):125-6. PubMed ID: 15223719
    [No Abstract]   [Full Text] [Related]  

  • 58. Therapy insight: management of cardiovascular disease in the renal transplant recipient.
    Rigatto C; Parfrey P
    Nat Clin Pract Nephrol; 2006 Sep; 2(9):514-26. PubMed ID: 16941044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular issues in dialysis patients: challenges and newer insights.
    Guzon OJ; Dellsperger KC
    Adv Perit Dial; 2006; 22():111-5. PubMed ID: 16983952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Global risk stratification in primary hypertension: the role of the kidney.
    Leoncini G; Ratto E; Viazzi F; Conti N; Falqui V; Parodi A; Tomolillo C; Deferrari G; Pontremoli R
    J Hypertens; 2008 Mar; 26(3):427-32. PubMed ID: 18300851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.